In Phase C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Participants will receive treatment right up until disease progression or even the participants are unable to tolerate the study drugs. Possible new ways for the prognosis and treatment of AML. (A) https://abbv-744-brd4-inhibition80134.blogdeazar.com/32214485/the-fact-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-that-no-one-is-suggesting